News - Valeant Pharmaceuticals, Oncology

Filter

Popular Filters

Actavis pays Valeant $55M for drug rights; Incyte gets $25M milestone

02-05-2013

US generics major Actavis (NYSE: ACT), reportedly the subject of a stalled takeover bid from Canada's…

ActavisAntibiotics and Infectious diseasesFinancialGenericsINC280IncyteLicensingMetronidazole LotionNovartisOncologyPharmaceuticalResearchValeant Pharmaceuticals

Valeant Pharma buys US rights to Eisai's Targretin for $65 million upfront

21-02-2013

Canada's Valeant Pharmaceuticals International (TSX: VRX) says that it has acquired US rights for Targretin…

EisaiLicensingNorth AmericaOncologyPharmaceuticalTargretinValeant Pharmaceuticals

News briefs from Bayer, AstraZeneca and Valeant/Galderma

06-12-2012

German drug major Bayer (BAYN: DE) and partner Regeneron (Nasdaq: REGN) submitted a marketing application…

AstraZenecaBayerEuropeEyleaFaslodexGaldermaLicensingNorth AmericaOncologyOphthalmicsPerlanePharmaceuticalRegulationRestylaneValeant Pharmaceuticals

Eisai enters deals with Valeant and Minophagen

04-04-2012

The European subsidiary of Japanese drug major Eisai (TYO: 4523) and PharmaSwiss, a division of Canada-based…

bexaroteneEisaiHalavenLicensingMarkets & MarketingMinophagenOncologyPharmaceuticalValeant Pharmaceuticals

Back to top